NCT06858865

A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282

An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282 in Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Addpharma Inc. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228A in healthy subjects.

Detailed description

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety profiles of AD-228A compared with coadministration AD-2281 and AD-2282 in healthy subjects.

Conditions

• Primary Hypercholesterolaemia

Interventions

Type	Name	Description
DRUG	AD-228A	AD-228A Oral Tablet
DRUG	AD-2281 and AD-2282	AD-2281 Oral Tablet + AD-2282 Oral Tablet

Timeline

• Start date: 2025-07-12
• Primary completion: 2025-08-14
• Completion: 2025-08-14
• First posted: 2025-03-05
• Last updated: 2025-10-01

Locations

1 site across 1 country: South Korea